@article{ca0a0603a8e04214b75ad989fbc68d8c,
title = "Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity",
abstract = "We present a patient with positive medium titer MOG-IgG and progressive neurological decline whose clinical and radiological phenotype were not consistent with a MOG-IgG associated disorder and ultimately received a diagnosis of glioblastoma after brain biopsy and died 4 weeks later. This represents an important topic with a high frequency of MOG-IgG testing in clinical practice. Due to this there are increasing reports of MOG-IgG positivity in atypical clinical phenotypes, raising the possibility of false positives, which can have important implications. It is important to highlight that judicious clinical evaluation is needed when interpreting MOG-IgG results in atypical settings.",
keywords = "Antibody, False positive, Glioblastoma, MOG",
author = "Moein Amin and Mays, {Mary Ann} and David Polston and Flanagan, {Eoin P.} and Richard Prayson and Amy Kunchok",
note = "Funding Information: Dr Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr Flanagan has received funding from the NIH (R01NS113828). Dr Flanagan is a member of the medical advisory board of the MOG project. Dr Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. Dr. Mays Speakers Bureau for Allergan, Amgen and Teva. Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",
year = "2021",
month = dec,
day = "15",
doi = "10.1016/j.jneuroim.2021.577743",
language = "English (US)",
volume = "361",
journal = "Journal of neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
}